Old Web
English
Sign In
Acemap
>
authorDetail
>
Manish R. Patel
Manish R. Patel
Seattle Children's Research Institute
Cancer
Medicine
Pharmacokinetics
c-Met inhibitor
Phases of clinical research
3
Papers
20
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer.
2020
British Journal of Cancer
Martin H. Voss
Michael S. Gordon
Monica M. Mita
Brian I. Rini
Vicky Makker
Teresa Macarulla
David C. Smith
Andrés Cervantes
Igor Puzanov
Roberto Pili
Ding Wang
Shadia I. Jalal
Shubham Pant
Manish R. Patel
Rachel Neuwirth
Aaron Enke
Yaping Shou
Farhad Sedarati
Douglas V. Faller
Howard A. Burris
Show All
Source
Cite
Save
Citations (8)
A phase II study of the c-Met inhibitor tivantinib (tiv) in combination with FOLFOX for the treatment of patients (pts) with previously untreated metastatic adenocarcinoma of the distal esophagus, gastroesophageal (GE) junction, or stomach.
2015
Journal of Clinical Oncology
Shubham Pant
Manish R. Patel
Carla Kurkjian
Michael Brian Hemphill
Maria Regina C. Flores
Dana S. Thompson
Johanna C. Bendell
Show All
Source
Cite
Save
Citations (11)
Abstract A17: ME-344, a novel mitochondrial oxygenase inhibitor: Results from a first-in-human Phase I study.
2013
Molecular Cancer Therapeutics
Johanna C. Bendell
Manish R. Patel
Jeffrey R. Infante
Carla Kurkjian
Suzanne F. Jones
Shubham Pant
Howard A. Burris
John D. Hainsworth
Ofir Moreno
Kathleen Moore
Show All
Source
Cite
Save
Citations (1)
1